CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||20 mg tablet|
|Tumour Type||Skin and Melanoma|
|Funding Request||In combination vermurafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation|
|Pre Noc Submission||Yes|
|NOC Date||February 22, 2016|
|Manufacturer||Hoffmann-la Roche Ltd.|
|Sponsor||Hoffmann-la Roche Ltd.|
|Submission Date||December 11, 2015|
|Submission Deemed Complete||December 18, 2015|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||January 4, 2016|
|Check-point meeting||February 9, 2016|
|pERC Meeting||April 22, 2016|
|Initial Recommendation Issued||May 5, 2016|
|Feedback Deadline ‡||May 19, 2016|
|pERC Reconsideration Meeting||June 16, 2016|
|Final Recommendation Issued||June 30, 2016|
|Notification to Implement Issued||July 18, 2016|
|Therapeutic Area||Metastatic melanoma|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.